Chronic graft-vs.-host disease of the liver: Another indication of ursodeoxycholic acid?



Objective: To determine the safety and efficacy of ursodeoxycholic acid treatment in patients with chronic graft-versus-host disease (GVHD) of the liver.

Design: Open-label study in which each patient served as his or her own control.

Setting: Private practice and a university bone marrow transplant center.

Patients: Twelve patients with refractory chronic GVHD of the liver were studied after allogeneic bone marrow transplantation.

Interventions: After baseline data collection, patients were given ursodeoxycholic acid (UDCA, 10 to 15 mg/kg body weight per day) for 6 weeks. After discontinuation of the drug, patients were followed for an additional 6 weeks. Doses of immunosuppressive drugs were unchanged for these 12 weeks.

Measurements: Signs, symptoms, Karnofsky performance scores, hematocrit, total leukocyte count, absolute neutrophil count, platelet count, alanine aminotransferase (ALT), aspartate aminotrasferase (AST), alkaline phosphatase, gamma-glutamyltransferase (GGT), total serum bilirubin, prothrombin time.(Text missing).